Long-term evaluation of neurological outcomes in chemotherapy-associated posterior reversible encephalopathy (PRES) syndrome in children
Klinische Pädiatrie · 01.05.2025 · 237 (03) · 141-152
DOI: 10.1055/a-2468-3799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2025. Verfasst von Gökçe Pınar Reis İskenderoğlu und 4 weiteren Autor:innen. Beteiligte Einrichtung: pediatric hematology and oncology, Karadeniz Technical University, Trabzon, Turkey. Hauptthemen laut MEDLINE: Posterior Leukoencephalopathy Syndrome, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Background
Posterior reversible encephalopathy syndrome (PRES) is a clinical syndrome with numerous etiologies, mostly characterized by magnetic resonance imaging (MRI) abnormalities in the posterior cerebral white and gray matter and acute neurological symptoms.
Aim
To examine the predisposing factors, clinical results, and radiological features of PRES in children diagnosed with malignancy. Materials and Methods The study included 20 patients (7 F/13 M) aged 4–16 years at the time of diagnosis who were diagnosed with malignancy and developed PRES during chemotherapy.
Results
All the patients were diagnosed as having PRES both clinically and radiographically during chemotherapy. The time from the initiation of the chemotherapy to the onset of PRES ranged from 7–675 days. Hypertension was detected in nine patients, seizure was the most common presenting symptom – had involvement in the occipital and parietal lobes on MRI (n=14)/followed by headache (n=8)/altered consciousness (n=5)/visual impairment (n=4). Hydrocephalus and tentorial herniation were observed in one patient. Most of the lesions on MRI resolved within 10–33 days and the EEG findings within 9 months. Clinical symptoms of PRES also disappeared completely the 5-year Press frequency was found to be 2.48%.
Conclusion
PRES may complicate the oncological treatment in children. Hypertension is a leading risk factor for PRES, while it should be kept in mind that the blood pressure may be normal in chemotherapy-induced PRES cases. PRES should be included in the differential diagnosis of all patients receiving chemotherapy and presenting with acute neurological symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- pediatric hematology and oncology, Karadeniz Technical University, Trabzon, Turkey.
- pediatric neurology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey.
- pediatric neurology, Karadeniz Technical University, Trabzon, Turkey.
- radiology, Karadeniz Technical University Faculty of Medicine, TRABZON, Turkey.
ORCID-Profile: Beril Dilber
Zitieren
APA
Reis İskenderoğlu, G. P., Dilber, B., Eyüboğlu, İ., Bahadır, A., & Erduran, E. (2025). Long-term evaluation of neurological outcomes in chemotherapy-associated posterior reversible encephalopathy (PRES) syndrome in children. Klinische Pädiatrie, 237(03), 141-152. https://doi.org/10.1055/a-2468-3799
Vancouver
Reis İskenderoğlu GP, Dilber B, Eyüboğlu İ, Bahadır A, Erduran E. Long-term evaluation of neurological outcomes in chemotherapy-associated posterior reversible encephalopathy (PRES) syndrome in children. Klinische Pädiatrie. 2025;237(03):141-152. doi:10.1055/a-2468-3799
BibTeX
@article{Reisskenderolu2025,
author = {Reis İskenderoğlu, Gökçe Pınar and Dilber, Beril and Eyüboğlu, İlker and Bahadır, Ayşenur and Erduran, Erol},
title = {Long-term evaluation of neurological outcomes in chemotherapy-associated posterior reversible encephalopathy (PRES) syndrome in children},
journal = {Klinische Pädiatrie},
year = {2025},
volume = {237},
number = {03},
pages = {141--152},
doi = {10.1055/a-2468-3799}
}
EUVIMED